Provided by Tiger Trade Technology Pte. Ltd.

Vanguard Health Care ETF

319.37
-1.5950-0.50%
Volume:101.76K
Turnover:32.45M
Market Cap:19.22B
PE:34.67
High:319.67
Open:319.30
Low:317.21
Close:320.96
52wk High:330.75
52wk Low:249.57
Shares:60.18M
Float Shares:60.18M
Volume Ratio:1.68
T/O Rate:0.17%
Dividend:4.72
Dividend Rate:1.48%
EPS(TTM):9.21
EPS(LYR):41.51
ROE:3.75%
ROA:0.89%
PB:0.97
PE(LYR):7.69

Loading ...

Dow Jones Top Company Headlines at 11 am ET: GameStop Sees Higher Profit as eBay Investment Offsets Lower Sales | SLB ...

Dow Jones
·
22 mins ago

Exchange-Traded Funds, Equity Futures Lower Pre-Bell Monday as US, Iran Exchange Attacks

MT Newswires Live
·
1 hour ago

CVS Health remains top large cap pick in healthcare services at Jefferies

TIPRANKS
·
2 hours ago

States Namenda Tablets not Withdrawn for Safety or Effectiveness Reasons - Federal Register

THOMSON REUTERS
·
2 hours ago

FDA: Will not Begin Procedures to Withdraw Approval of Abbreviated New Drug Applications That Refer to Namenda Products - Federal Register

THOMSON REUTERS
·
2 hours ago

Lilly is Bigger than Ever. Why Its Latest $2.9 Billion Immunology Deal Makes Sense.

Dow Jones
·
2 hours ago

OneMedNet’s iRWD Platform Enables Rapid Feasibility-to-Delivery for Leading AI-Driven Drug Development Company

GlobeNewswire
·
2 hours ago

AbbVie to Present at Wells Fargo Healthcare Conference

Reuters
·
3 hours ago

Eli Lilly's Psoriasis Drug Trial Shows Sustained Positive Results

Dow Jones
·
3 hours ago

Lilly to Buy This Autoimmune Drugmaker for $2.9 Billion in Cash. What it Means for the Stock.

Dow Jones
·
3 hours ago

Eli Lilly announces 52-week results from TOGETHER-PsO, TOGETHER-PsA

TIPRANKS
·
4 hours ago

Eli Lilly - Taltz and Zepbound Lead to Deeper Improvements in Systemic Inflammation in Both Trials

THOMSON REUTERS
·
4 hours ago

New Phase 3B Data on Lilly's Taltz (Ixekizumab) and Zepbound (Tirzepatide) Used Together Showed Improved and Durable Efficacy at One Year in Adults with Psoriatic Disease and Obesity

THOMSON REUTERS
·
4 hours ago

Eli Lilly - Taltz and Zepbound Maintain or Improve Disease Activity at Week 52 Versus Taltz Alone

THOMSON REUTERS
·
4 hours ago

Eli Lilly: Adverse Events in Participants Treated with Taltz and Zepbound Together were Generally Mild to Moderate

THOMSON REUTERS
·
4 hours ago

Lilly to Acquire Merida Biosciences in Deal Worth up to USD 2.88 Billion

Reuters
·
4 hours ago

Eli Lilly: Under Terms of Agreement, Lilly Will Acquire Merida and Pay up to $2.875 Bln in Cash

THOMSON REUTERS
·
4 hours ago

Lilly to Acquire Merida Biosciences to Advance Treatments for Serious Autoimmune and Allergic Diseases

THOMSON REUTERS
·
4 hours ago

Eli Lilly - Deal Expected to Close in Q4 2026 Subject to Regulatory Approvals

THOMSON REUTERS
·
4 hours ago

Tissue Repair Limited Confirms ASX-Aligned Governance for 2026

TIPRANKS
·
8 hours ago